Erica Fong

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Stephen A. Harrison, Peter Ruane, B. Freilich et al. · Nature Medicine · 2021 · 342 citations

Medicine, Internal Medicine, Pharmacotherapy +10

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Stephen A. Harrison, Juan P. Frías, Guy Neff et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 235 citations

Medicine, Pharmacology, Pharmacotherapy +8

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Stephen A. Harrison, Peter Ruane, B. Freilich et al. · JHEP Reports · 2022 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Mazen Noureddin, Juan P. Frías, Guy Neff et al. · The Lancet · 2025 · 42 citations

Medicine, Pharmacology, Pharmacotherapy +9